The investment bank said that Exagen is poised for growth with a differentiated autoimmune test that outperforms conventional biomarker-based tests.

The test was developed in collaboration with Eli Lilly and can be used with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline.

The cash deal includes ambulatory outreach laboratory services in 13 states and includes patient service centers and in-office phlebotomy sites.

The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.